根治性放疗后复发性/残留宫颈癌的子宫切除术。
Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy.
机构信息
Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
Department of Obstetrics and Gynecology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
出版信息
In Vivo. 2020 Jul-Aug;34(4):2173-2177. doi: 10.21873/invivo.12026.
Abstract
BACKGROUND/AIM: Radical hysterectomy has been used for local recurrent or persistent (LR) cervical cancer after radiotherapy (RT), but the rate of serious complications is high and tolerance is low. This study determined the efficacy, safety, and prognostic factors of adjuvant simple hysterectomy in LR cervical cancer post-RT.
PATIENTS AND METHODS
A total of 21 patients who underwent hysterectomy for LR cervical cancer post-RT in our Department between May 2007 and September 2018 were included in the study. Primary, definitive RT was performed. Histological response by definitive RT in the extirpated uterus was classified on the basis of histological response criteria: effect (Ef) 0-3.
RESULTS
The 5-year overall survival (OS) and disease-free survival (DFS) rates were 51.9% and 50.1%, respectively. Ef 1 was significantly associated with poorer prognosis compared to Ef 2 or Ef 3.
CONCLUSION
Adjuvant hysterectomy could be a treatment of choice for LR cervical cancer post-RT.
摘要
背景/目的：根治性子宫切除术已被用于放疗（RT）后局部复发或持续性（LR）宫颈癌，但严重并发症发生率高，耐受性低。本研究旨在确定 LR 宫颈癌根治性放疗后辅助单纯子宫切除术的疗效、安全性和预后因素。
患者和方法
本研究纳入了 2007 年 5 月至 2018 年 9 月我科因 LR 宫颈癌接受子宫切除术的 21 例患者。行原发性、根治性 RT。根据切除子宫的组织学反应标准，将根治性 RT 的组织学反应分为：有效（Ef）0-3。
结果
5 年总生存率（OS）和无病生存率（DFS）分别为 51.9%和 50.1%。Ef 1 与 Ef 2 或 Ef 3 相比，预后明显较差。
结论
辅助性子宫切除术可能是 LR 宫颈癌根治性放疗后的一种治疗选择。
相似文献
1
Hysterectomy for Recurrent/Residual Cervical Cancer Following Definitive Radiotherapy.根治性放疗后复发性/残留宫颈癌的子宫切除术。
In Vivo. 2020 Jul-Aug;34(4):2173-2177. doi: 10.21873/invivo.12026.
2
Radical hysterectomy after radiotherapy for recurrent or persistent cervical cancer.复发性或持续性宫颈癌放疗后行根治性子宫切除术。
Int J Gynaecol Obstet. 2017 Nov;139(2):185-191. doi: 10.1002/ijgo.12284. Epub 2017 Sep 6.
3
Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy.国际妇产科联盟（FIGO）IB期无淋巴结转移宫颈癌的预后因素及根治性子宫切除术后辅助放疗的作用
Int J Gynecol Cancer. 2004 Mar-Apr;14(2):286-92. doi: 10.1111/j.1048-891X.2004.014212.x.
4
[Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].[新辅助化疗联合根治性子宫切除术治疗无高危因素的Ⅰb2期和Ⅱa2期宫颈鳞癌的预后分析]
Zhonghua Fu Chan Ke Za Zhi. 2018 Apr 25;53(4):248-256. doi: 10.3760/cma.j.issn.0529-567x.2018.04.008.
5
Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).FIGO IB1期宫颈癌且具有中度危险因素患者根治性子宫切除术后辅助放疗对结局和并发症影响的分析（GOTIC研究）
World J Surg Oncol. 2016 Jun 29;14(1):173. doi: 10.1186/s12957-016-0931-4.
6
Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer.根治性子宫切除术联合辅助放疗与单纯根治性放疗治疗 FIGO 分期 IIB 宫颈癌的比较。
Gynecol Oncol. 2011 Nov;123(2):241-7. doi: 10.1016/j.ygyno.2011.07.009. Epub 2011 Aug 6.
7
Salvage radiotherapy strategy and its prognostic significance for patients with locoregional recurrent cervical cancer after radical hysterectomy: a multicenter retrospective 10-year analysis.根治性子宫切除术治疗后局部区域复发性宫颈癌患者的挽救性放疗策略及其预后意义：一项多中心回顾性 10 年分析。
BMC Cancer. 2023 Sep 26;23(1):905. doi: 10.1186/s12885-023-11406-z.
8
[Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].[根治性子宫切除术治疗复发性Ⅰb-Ⅱa期宫颈鳞癌的预后因素及治疗模式分析]
Zhonghua Fu Chan Ke Za Zhi. 2019 Jun 25;54(6):399-405. doi: 10.3760/cma.j.issn.0529-567x.2019.06.008.
9
Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028).腹腔镜与腹式根治性子宫切除术治疗早期宫颈癌患者（无辅助治疗）的比较：韩国妇科肿瘤学组研究（KGOG 1028）的辅助分析。
Gynecol Oncol. 2019 Sep;154(3):547-553. doi: 10.1016/j.ygyno.2019.06.023. Epub 2019 Jul 1.
10
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.与传统放疗相比，调强放疗治疗宫颈癌根治术后盆腔局部复发的回顾性研究
Int J Gynecol Cancer. 2015 Jul;25(6):1058-65. doi: 10.1097/IGC.0000000000000360.
引用本文的文献
1
Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort.三维打印非共面模板（3D-PNCT）辅助高剂量率组织间近距离放疗（HDR-ISBT）用于复发性宫颈癌再程放疗的疗效和安全性：一项前瞻性队列研究
J Gynecol Oncol. 2025 Mar;36(2):e20. doi: 10.3802/jgo.2025.36.e20. Epub 2024 Jul 4.
2
Clinical study of interstitial brachytherapy for 72 cases of recurrent cervical cancer.72例复发性宫颈癌组织间近距离治疗的临床研究
Pak J Med Sci. 2023 May-Jun;39(3):863-869. doi: 10.12669/pjms.39.3.6868.
3
Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy.根治性放化疗后残余或复发宫颈癌的挽救性高强度聚焦超声治疗。
Front Immunol. 2022 Oct 17;13:995930. doi: 10.3389/fimmu.2022.995930. eCollection 2022.
本文引用的文献
1
Adjuvant Hysterectomy in Patients With Residual Disease After Radiation for Locally Advanced Cervical Cancer: A Prospective Longitudinal Study.局部晚期宫颈癌放疗后残留病灶患者的辅助性子宫切除术：一项前瞻性纵向研究。
J Glob Oncol. 2019 Jan;5:1-7. doi: 10.1200/JGO.18.00157.
2
Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer.日本妇科肿瘤学会 2017 年子宫颈癌治疗指南。
Int J Clin Oncol. 2019 Jan;24(1):1-19. doi: 10.1007/s10147-018-1351-y. Epub 2018 Oct 5.
3
Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.顺铂与紫杉醇周疗同步放化疗用于局部晚期子宫颈癌患者的II期研究：JACCRO GY-01试验
Gynecol Oncol. 2016 Feb;140(2):253-8. doi: 10.1016/j.ygyno.2015.12.008. Epub 2015 Dec 14.
4
Histological assessment of therapeutic response in breast cancer.乳腺癌治疗反应的组织学评估
Breast Cancer. 2016 Jul;23(4):540-5. doi: 10.1007/s12282-013-0499-6. Epub 2013 Oct 31.
5
Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.局部晚期子宫颈癌高剂量率腔内近距离放疗同期放化疗的 II 期研究：低累积剂量方案的疗效和毒性。
Gynecol Oncol. 2012 Aug;126(2):211-6. doi: 10.1016/j.ygyno.2012.04.036. Epub 2012 Apr 30.
6
Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.紫杉醇和顺铂同步放化疗治疗宫颈癌腺癌。
Anticancer Res. 2012 Apr;32(4):1475-9.
7
Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.日本妇科肿瘤学组研究（JGOG1066）的放射治疗质量保证：子宫颈癌同期放化疗的合作 II 期研究。
Int J Clin Oncol. 2011 Aug;16(4):379-86. doi: 10.1007/s10147-011-0196-4. Epub 2011 Feb 18.
8
Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.新辅助化疗后乳腺癌的病理学：标本处理与报告建议概述
Arch Pathol Lab Med. 2009 Apr;133(4):633-42. doi: 10.5858/133.4.633.
9
Adjuvant hysterectomy for treatment of residual disease in patients with cervical cancer treated with radiation therapy.辅助性子宫切除术用于治疗接受放射治疗的宫颈癌患者的残留病灶。
Br J Cancer. 2008 Oct 21;99(8):1216-20. doi: 10.1038/sj.bjc.6604619.
10
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.术前化疗：国家外科辅助乳腺和肠道项目协议B - 18和B - 27的更新
J Clin Oncol. 2008 Feb 10;26(5):778-85. doi: 10.1200/JCO.2007.15.0235.
Zotero 插件